Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pPML7789 + pPJV2012
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal (via Particle-mediated Epidermal Delivery)
01
Overview
pPML7789 + pPJV2012 is a combination of two DNA vaccines developed by PowderMed for use as a potential vaccine against pandemic influenza. Both components are delivered using Particle Mediated Epidermal Delivery (PMED), a needle-free technology that delivers DNA-coated gold particles into the skin. The combination is designed to induce an immune response capable of protecting against novel or pandemic strains of influenza. Clinical studies have evaluated its safety, tolerability at administration sites, and immunogenicity in healthy adult volunteers[2]. At least one component (pPJV2012) has also been studied as a DNA vaccine with an encoded immunostimulator and has been investigated for other indications such as herpes simplex virus infection[7].
02
Targets
HA0 (Influenza B virus hemagglutinin)IL12 (Interleukin-12)
Beyond the preview
Go deeper on pPML7789 + pPJV2012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pPML7789 + pPJV2012.